ArticleJournal of cancer therapy2014
SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.
Article in Journal of cancer therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer.Frontiers in immunology · 2026Article
- Integrating differential gene expression and Mendelian randomization analyses reveal novel gene for prognosis, immune response, and drug sensitivity in lung cancer.Discover oncology · 2025Article
- Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.European journal of medical research · 2024Review
- Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Candida Administration Worsens Neutrophil Extracellular Traps in Renal Ischemia Reperfusion Injury Mice: An Impact of Gut Fungi on Acute Kidney Injury.Journal of innate immunity · 2022Article
- Acute Kidney Injury Induced Lupus Exacerbation Through the Enhanced Neutrophil Extracellular Traps (and Apoptosis) in Fcgr2b Deficient Lupus Mice With Renal Ischemia Reperfusion Injury.Frontiers in immunology · 2021Article
- Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.Brain pathology (Zurich, Switzerland) · 2020Article
- Nanocarriers as Magic Bullets in the Treatment of Leukemia.Nanomaterials (Basel, Switzerland) · 2020Review
- National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.Oncotarget · 2018Article
- Syk inhibitors in clinical development for hematological malignancies.Journal of hematology & oncology · 2017Review
- Recent advances and novel treatment paradigms in acute lymphocytic leukemia.Therapeutic advances in hematology · 2016Review
- Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.Oncotarget · 2016Article
- Review
- Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia.Haematologica · 2015Article
- Application of oncoproteomics to aberrant signalling networks in changing the treatment paradigm in acute lymphoblastic leukaemia.Journal of cellular and molecular medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The identification of SYK as a master regulator of apoptosis controlling the activation of the PI3-K/AKT, NF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.